Bicara Therapeutics Inc.

Bicara Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts that focuses on developing bifunctional antibody therapies targeting solid tumors. The company's approach combines two distinct biological functions within a single therapeutic molecule to address cancer indications where existing treatments have shown limited efficacy.

The company's lead program is ficerafusp alfa, a bifunctional antibody designed to simultaneously target epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β). This dual-mechanism approach aims to block tumor growth signaling while reducing the immunosuppressive microenvironment characteristic of solid tumors. The ficerafusp alfa program represents the company's primary clinical development effort and pipeline focus.

Bicara operates as a development-stage enterprise with approximately 55 full-time employees. As a pre-revenue clinical-stage company, the organization has not yet commercialized therapeutics and remains dependent on capital financing to fund ongoing research and development activities. The company was incorporated in Delaware in 2018 and maintains operations from its Boston headquarters.